spective study of the safety and efficacy of catheter ablation.
Methods and Results. From August 1987 through March 1990, the study comprised 136 patients in whom only DC energy was used in attempted production of third-degree atrioventricular block to treat uncontrollable supraventricular tachycardias. Eight patients died during hospitalization for ablation. In seven (5.1%), the ablation may have contributed to their deaths. Causes of death included ventricular fibrillation (five patients, three with polymorphic ventricular tachycardia), progressive heart failure (one patient), and respiratory failure (two patients, one dying after resuscitation from ventricular fibrillation). Compared with survivors, patients who died were more likely to have had prior aborted sudden death (38% versus 2%, p<0.05), congestive heart failure (88% versus 22%,p<0.001), cardiomyopathy (50% versus 16%, p<0.05), lower baseline systolic blood pressure (106 versus 138 mm Hg, p<0.001), prolonged baseline and postablation corrected QT interval (p<0.01), and markedly reduced ejection fraction (27% versus 52%, p<0.001). Ablation successfully produced third-degree atrioventricular block in 88% of the patients who died and in 83% of survivors.
Conclusions. Catheter ablation of the atrioventricular junction with DC energy carries a significant, previously unrecognized risk of death (5.1%), particularly from lethal arrhythmias, when applied to patients with severe left ventricular dysfunction. Great care should be taken in these seriously ill patients to guard against postablation ventricular arrhythmias. (Circulation 1991; 84:1924 -1937 Ca atheter ablation for control of cardiac arrhythmias involves directed destruction of small areas of cardiac tissue. Since its inception in 1982,1,2 catheter ablation of the atrioventricular junction has gained widespread acceptance as a means for producing third-degree atrioventricular block to control drug-resistant supraventricular tachycardias, especially atrial fibrillation. The majority of catheter ablations have been performed using high-examine predictors of safety and efficacy. A controlled clinical trial was not deemed ethical because patients considered for ablation had usually failed therapy with numerous conventional and experimental drugs, and ablation was offered as a tactic of last resort. The multicenter nature of the present study allowed for efficient gathering of sufficient numbers of patients to draw inferences about the safety and efficacy of the ablation efforts. Since August 1987, the CAR has collected data on catheter ablation involving all areas of the heart, including the atrium, atrioventricular junction, and ventricle and using both high-energy DC and radiofrequency energy modalities.
In this report we analyze mortality in the patient subgroup with attempted ablation of the atrioventricular junction using DC energy, assess the risk factors for death, discuss the possible mechanisms for death, review prior studies of atrioventricular junction ablation, and offer clinical guidelines directed at prevention of lethal complications in patients with catheter ablation of the atrioventricular junction using DC energy.
Methods

Description of CAR
CAR evolved from a pilot registry, the Percutaneous Cardiac Mapping and Ablation Registry (PCMAR).6 PCMAR was a voluntary, retrospective, international registry. CAR is a 5-year, international, multicenter, prospective cohort study of catheter ablation supported by funds from the National Institutes of Health, Bethesda, Md. CAR patient enrollment began in August 1987 and ended on March 31, 1990 . Data were collected prospectively by the investigators and study coordinators at 16 Measurement of the QT interval on the 12-lead electrocardiogram (ECG) was made using calipers. The longest OT interval was measured, usually in one of the midprecordial leads where the end of the T wave was clearly visible, using the prior RR cycle for calculation of the heart rate when the rhythm was regular and using an average of several cycles when the rhythm was irregular. The U wave was not included in the measurements.
A detailed hospitalization summary regarding each patient who died was submitted by the clinical investigator. Medication use and results of electrolyte determinations at the time of death were obtained for these patients. However, for the patients who survived, these data were not collected. External review of all deaths was conducted by the independent CAR Mortality Committee. Committee members are not from any institution contributing data on ablation procedures. The definition of a procedurerelated death is one that occurred unexpectedly in the hospital after the ablation procedure or one that appeared to be directly related to the ablating shock. General Technique of Catheter Ablation of Atrioventricular Junction Consistent with physicians' usual practices, a variety of techniques were used in the 16 clinical centers. Premedication with benzodiazepines was used in some centers. A patch electrode of 10-25 cm in diameter was placed at the left scapula. A catheter from 4F to 7F in size was inserted percutaneously into the subclavian, internal jugular, or femoral vein and advanced into the right ventricular apex for use as a temporary pacing wire. A catheter from 4F to 7F in size was inserted into the femoral vein and advanced to the right atrium for pacing and recording. A 6F or 7F tripolar or quadripolar USCI catheter was inserted into the femoral vein and advanced across the tricuspid valve for recording of His and atrial potentials and delivery of the ablation shock. Systemic arterial blood pressure monitoring was performed. The shock was delivered through a distal electrode showing either the largest His deflection or the largest His deflection and the largest atrial deflection. The patient was anesthetized with either shortacting benzodiazepines, barbiturates, or etomidate. Shocks of 160-360 J, in which the catheter was usually connected as the cathode, were then delivered. If third-degree atrioventricular block was produced after the first shock, many physicians delivered a repeat shock of the same amplitude after 5-10 minutes. If third-degree atrioventricular block was not produced after the first shock, two to six repeat shocks were administered. After 5-15 minutes of stable third-degree atrioventricular block, the His potential was measured, and the escape rhythm was determined. After minutes, the atrial, His, and arterial catheters were withdrawn. Blood was drawn for creatine phosphokinase (CPK) determinations at 6-48 hours. A permanent pacemaker was inserted after 12-72 hours. Baseline Hemodynamic Status at Ablation Session At entry to the final ablation session, four patients who later died had severe congestive heart failure or were in shock. Two patients (6 and 7; Table 3 ) were being considered for cardiac transplantation. Three patients (3, 4, and 7; Table 3 ) had preanesthetic systolic blood pressure measurements of less than 100 mm Hg before the ablation procedure, and patients 3 and 7 were receiving inotropic support. One patient (6) had an ablation during intra-aortic balloon counterpulsation. In contrast, no patients in the group of survivors had preanesthetic systolic blood pressure measurements of less than 100 mm Hg (p<0.001). Anesthesia lowered systolic blood pressure by similar amounts in the two groups of patients. Table 4 shows the types of anesthesia used and the blood pressure measurements recorded at baseline (before anesthesia), immediately after ablation, and 15 minutes after ablation in the group of patients who died. We did not collect data on blood pressure after anesthesia induction but did collect data on pressure immediately before the first ablation shock. Barbiturate anesthesia was used, either alone or in combination with other agents in five patients (1, 3, 6, 7, and 8; Tables 3 and 4 ). Two of these latter patients (3 and 7) were hemodynamically compromised at entry to the ablation session. Mean systolic blood pressure in these five patients decreased from 104 mm Hg at the preanesthetic measurement to 92 mm Hg after the ablation shock(s) compared with a decrease of 111 to 105 mm Hg, respectively, in those not receiving barbiturate anesthesia. Ablation Session Data The duration of the last ablation session was 2.4±0.8 hours in patients who died and 2.6+1.5
hours in survivors (p=0.11). Patients who died received fewer shocks and less cumulative delivered energy and had lower postablation CPK-MB fractions than survivors, but the differences were not statistically significant. The measurements for systolic arterial blood pressure are shown in Table 5 Comparison of baseline and postablation heart rates is shown in Figure 1 . As expected, mean heart rates in this group were significantly slower after ablation. Three patients had sinus rhythm at baseline, all of whom developed third-degree atrioventricular block after the ablation procedure. Two of these patients died as a result of cardiac arrhythmias, and one died from noncardiac causes. Ejection fractions in these patients were 13%, 19%, and 16%, respectively.
Mechanism of Death in Patients Who Died
All patients who died had antecedent organic heart disease ( (Figure 2 ). Third-degree atrioventricular block with ventricular pacing and premature ventricular complexes were present. The ventricular complex initiating the torsades occurred after the terminal portion of the T wave in all three cases. Postmortem examination in patient 2 revealed a recent myocardial infarction of the apical-lateral free wall dating approximately from the time of the ablation. Patient 4 died of acute cardiovascular collapse 6 days after the ablation, but no rhythm strips were saved. Forty-eight hours earlier, she had suffered a cardiac arrest in which ventricular fibrillation was noted, but again, no rhythm strips were saved. She had a preablation history of aborted sudden death while receiving quinidine, and she had been treated with procainamide therapy to suppress ventricular ectopy during the 24 hours before her episode of ventricular fibrillation. Thus, the role of the ablation session in this patient's death may have been fortuitous, and her ventricular fibrillation might have been related instead to the proarrhythmic effect of procainamide. Two other patients suffered ventricular fibrillation during the postablation period. Patient 5 experienced ventricular fibrillation 90 minutes after the last ablation shock and died 32 days later as a result of pulmonary complications resulting from the intubation that accompanied the resuscitation efforts. Patient 6 entered the ablation session requiring intraaortic balloon counterpulsation for hemodynamic support. He experienced ventricular fibrillation 7 days after his last ablation, with the development of severe anoxic encephalopathy. He was found pulseless with a regular rhythm 4 days later.
Patient 7 entered the ablation session with severely depressed ventricular function requiring intravenous dopamine. His preanesthetic blood pressure was 98/68 mm Hg. Pentathol and versed were administered, and a single 200-J shock was delivered, immediately after which his blood pressure was recorded at 64/54 mm Hg. There was no recording of the blood pressure between administration of pentathol and delivery of the ablation shock, so it is not known whether the barbiturate further depressed myocardial contractility. He died of progressive heart failure 7 days later despite intra-aortic balloon h(J' Autopsy data were available for five of the eight patients who died. Four died an arrhythmic death. In three of the four, the ventricular septum was specifically examined and showed no abnormalities. The fourth patient died of heart failure, and the summit of the ventricular septum was normal. Other autopsy findings are shown in Table 6 .
Production of Third-Degree Atrioventricular Block and Postablation Pacemaker Rates
The intent of the ablation procedure in all patients was the production of third-degree atrioventricular block, which was present at death in seven patients who died (88%) and 106 survivors at hospital discharge (83%) (p=NS). For the entire group, thirddegree atrioventricular block was produced in 83%. New ventricular pacemakers were implanted in six patients who died and 108 survivors. The postablation pacing rates for patients with VVI pacemakers averaged 73 beats/min in patients who died (n=6) and 71 beats/min in survivors (n=90) (p=NS). Logistic regression revealed that the postablation pacing rate was not predictive of death.
Role of QT Interval in Predicting Development of Polymorphic Ventricular Tachycardia or Ventricular Fibrillation
Corrected QT (QTj) intervals in the baseline and postablation 12-lead ECGs were plotted for two groups. The results are shown in Figures 3 and 4 and Table 7 . The groups were the nine patients who had either ventricular fibrillation (n=3) or fatal (n=3) or nonfatal (n=3) polymorphic ventricular tachycardia as compared with the survivors plus the two patients who died of nonarrhythmic causes. ECGs were available for 125 patients at baseline and 106 patients after ablation. Data were not collected on antiarrhythmic drug use in the survivors or the two patients who died of nonarrhythmiarelated causes at the time of ECG recording. However, in the group with ventricular arrhythmias, three of five patients at baseline and two of four patients after ablation had QT, values that were above the mean and were receiving antiarrhythmia medications. In comparison, one of four patients at baseline and one of four patients after ablation had QTC values that were below the mean and were receiving antiarrhythmia medications. The one patient whose QT, value was an extreme outlier was receiving amiodarone. The mean values for baseline and postablation QT, intervals were significantly different between the two groups (logistic regression, p< 0.01 for both categories). ablation, however, as demonstrated in Figure 2 , there were prominent U waves in the postpause complexes in two of the three patients with documented polymorphic ventricular tachycardia.
Clinical Course in Patients With Markedly Reduced Ejection Fraction or Polymorphic Ventricular Tachycardia in Survivors
Three patients in the group of survivors had a left ventrictular ejection fraction of less than 20%. One of these patients (ejection fraction, 19%) had documented polymorphic ventricular tachycardia in the postablation period and died from congestive heart failure secondary to ischemic cardiomyopathy. The other two patients had no complications and were well at their last follow-up examination.
Polymorphic ventricullar tachycardia in the setting of ventricular pacing for third-degree atrioventricular block was reported in three survivors in the postablation period, but the true incidence of this arrhythm in the survivors is unknown.
One patient experienced PMVT degenerating into ventricular fibrillation in the setting of quinidine therapy and hypokalemia (serum K', 3.4 meq/l) and was successfully defibrillated. Another patient died suddenly 10 weeks after the ablation, probably from a pulmonary embolus. The third patient died from congestive heart failure secondary to ischemic cardiomyopathy. This patient developed polymorphic ventricular tachycardia while receiving amiodarone and had documented hypokalemia in the postablation period (serum K', 3.1 meq/l). Baseline ejection fractions in these three patients were 50%, 52%, and 19%, respectively.
Discussion
This is the first international, multicenter, prospective study of the safety and efficacy of electrode catheter ablation for control of drug-refractory cardiac arrhythmias. The major finding to date was the uinexpectedly high rate of deaths possibly related to the procedure during hospitalization encompassing DC ablation of the atrioventricular junction (seven of 136 patients, or 5.1%). In the largest previously reported retrospective series of DC catheter ablation of the atrioventricular junction, only two of 551 patients (0.4%) died during hospitalization encompassing the ablation session-one from ventricular fibrillation 7 days after ablation and the other 2 weeks after ablation from heart failure resulting from a perforation of a septal aneurysm. 3 Patients who died were frequently gravely ill on entry to the ablation session. Two were being considered for cardiac transplantation, three were hypotensive on entry to the laboratory, two required intravenous inotropic support, and one required intra-aortic balloon counterpulsation. Obviously, they represented a group already at high risk for any procedure that might cause further hemodynamic deterioration. One of these patients suffered further acute hemodynamic compromise as a result of either the ablation shock or the administration of barbiturate anesthesia and later died of heart failure.
High-energy DC ablation catheter discharges of 200-300 J are associated with an average generation of 2-3 kV, 20-40 A current, and 10-20 atm of pressure.7 These acute electromechanical disturbances have significant effects on the myocardial action potentials. Microscopic disruption of tissue may be arrhythmogenic.
In the present series, ventricular fibrillation occurred in six of the seven patients who died of cardiac causes. In three of these six patients, polymorphic ventricular tachycardia was documented in the setting of a long QT interval, associated with documented hypokalemia or a history of severe electrolyte abnormalities. One of these latter patients had a recent myocardial infarction that combined with electrolyte abnormalities in the postablation period, may have created a substrate conducive to the development of the lethal ventricular arrhythmia. For the other three patients in the present study who developed ventricular fibrillation, rhythm strips were not available before the onset of the terminal arrhythmia. However, in one of these patients, there was a prior history of aborted sudden death due to quinidinerelated torsade de pointes, and death occurred after therapy with procainamide had been instituted. In another, a low serum potassium level was recorded before the arrhythmia. In the two patients in this series with nonarrhythmic deaths, one died of cardiogenic shock, and one died of noncardiac problems that antedated the ablation procedure.
Three of the patients who died had sinus rhythm on their baseline ECGs, all of whom had ejection fractions of less than 20% and developed thirddegree atrioventricular block. Two of these three patients had arrhythmic deaths. One might speculate that the loss of the atrial contribution to ventricular filling caused a reduction in cardiac output that might have been contributory to either arrhythmia development or failure of resuscitative efforts. In addition, the faster baseline heart rate in patients who had atrial fibrillation before ablation may have resulted in a higher cardiac output than ventricular pacing without a heightened rate response.
Necrosis of the summit of the ventricular septum has been theorized as a factor in the development of ventricular arrhythmias in patients with ablation of the atrioventricular junction. In hospitals in which ablation is not a routine procedure, histological section of this part of the ventricle was not a standard part of the post-mortem cardiac examination. As stated above, there were no abnormalities of the ventricular septum noted in three of the four patients dying an arrhythmic death in whom data were available. Therefore, the data suggest that this area probably is not implicated in the genesis of the lethal arrhythmias in patients who died.
Three cases of polymorphic ventricular tachycardia were recorded in the postablation period in the group of survivors. One of these patients died suddenly 10 weeks after the ablation, but the death was probably related to a pulmonary embolus. Postablation rhythm strips in one of these patients showed a prolonged QT interval and a QRS pattern of the torsades de pointes type. The relation of a prolonged QTC interval to the development of ventricular arrhythmias is provocative (Figure 3 ). This measurement appeared to be predictive of development of polymorphic ventricular tachycardia or fibrillation. The finding of death resulting from polymorphic ventricular tachycardia was unexpected. When the data forms were constructed in 1986, we collected data on prior antiarrhythmic medications only. It was not feasible to determine in a retrospective manner what drugs were being administered at the time of recording the ECGs used for QT measurements. Thus, the role of antiarrhythmic drugs or electrolyte abnormalities in producing these changes was unknown, and these important findings require further investigation. There was documented hypokalemia in some of the patients who experienced polymorphic ventricular tachycardia.
Others have reported torsade de pointes in association with a variety of factors, including marked bradycardia and high-degree or complete atrioven-tricular block and in the setting of ventricular pacing. [8] [9] [10] [11] [12] [13] The mechanism for the arrhythmia may relate to bradycardia-dependent augmentation of early afterdepolarizations producing triggered activity.14 Torsades has been described soon after the spontaneous conversion of atrial fibrillation to sinus rhythm in patients receiving antiarrhythmic drugs. In patients with torsades secondary to antiarrhythmic drug administration, one half develop the arrhythmia within the first 4 days of therapy.14 The true role of torsades in causing death in the present series cannot be truly evaluated as long as the actual postablation incidence is unknown in the group of survivors. Patients who died had significantly less ventricular ectopy on baseline 24-hour Holter monitoring than survivors. It might be postulated that ablation was arrhythmogenic in these patients.
Role of Left Ventricular Ejection Fraction
In the present series, five of the eight patients who died had ejection fractions of less than 20%, whereas only three of the 128 survivors had ejection fractions at this level. Interestingly, of the eight patients who died, only one died of heart failure exacerbated by the ablating shock. The majority died of ventricular fibrillation. One of these latter patients suffered an acute myocardial infarction at the time of the ablation or shortly thereafter. In the entire group of the present series, there was a 7% prevalence of ejection fraction values of less than 20%, whereas in the PCMAR series,3 there was an 8% prevalence. In this earlier series, however, ejection fraction data were available on only 160 patients (29%). Patients in the present study might have had more severe ventricular dysfunction -only 32% were free of structural heart disease -compared with 46% in the PCMAR. These differences also reflect the evolutionary nature of the ablation procedure in that ablation therapy is now being offered to sicker patients. Thus, the two series cannot be strictly compared.
Barbiturate anesthesia, a myocardial depressant, may have caused hypotension in the immediate postablation period in the five patients who received it. Three of these patients were hypotensive before anesthesia, and the one patient in this group whose blood pressure decreased after the ablation was the patient who died of pump failure. It is not possible to determine the exact role of anesthesia in this patient.
It should be emphasized that there are no comparable data on outcome of acute interventions to permanently alleviate supraventricular tachycardias in patients who are gravely ill and hypotensive and have severe left ventricular failure. It is not surprising that there is a high mortality rate in this patient group. Nevertheless, catheter ablation, if successful, may actually improve ventricular performance if it allows for relief of cardiomyopathy resulting from tachycardia alone. There is a need for development of inclusion criteria and contraindications to ablation in this patient group. It is critical to note that many of the deaths in the present series resulted from ventricular arrhythmias usually considered to be due to transient electrolyte alterations, drugs, or acute heart rate changes. These factors might be manageable in the hospital setting.
In-Hospital Mortality After Atrioventricular Junction Ablation in Previously Reported Studies
There have been at least 18 prior studies of DC ablation of the atrioventricular junction, and they have involved 1,062 patients.1-5,15-26 However, two of these34 are registries that contain patients reported in other studies. Nevertheless, the total number of patients summarized approximates 800. Of this total, only three deaths (0.4%) were reported during hospitalization encompassing the ablation session. The first death was from ventricular fibrillation 7 days after the ablation26; the second death was from ventricular tachycardia 3 days after the ablation; and the third death was from heart failure resulting from perforation of a septal aneurysm. The true incidence rates of death and complications were unknown. There is a striking disparity between the previously reported 0.4% in-hospital death rate and the 5.1% procedure-related death rate reported in the present series. As stated above, it is possible that because sicker patients are now being ablated, procedurerelated mortality can also be expected to increase.
Efficacy of the ablation procedure has improved with experience. The long-term production of thirddegree atrioventricular block in the PCMAR series was 64% compared with 82% in the present series. Many of the largest clinical centers contributed data to both series. It is possible that a registry may be the best available format for evaluating new ablation techniques and evolving ablation technologies.
Clinical Implications
The majority of deaths in this series were due to either ventricular tachycardia degenerating into ventricular fibrillation or primary ventricular fibrillation. Polymorphic ventricular tachycardia consistent with torsades de pointes was documented in three patients. Hypokalemia or a serum potassium at the lower limits of normal was present. Another patient received a type Ia antiarrhythmic agent. The QT, interval was significantly longer in the patients who died of arrhythmia-related causes or experienced polymorphic ventricular tachycardia.
Many of these deaths appeared to be potentially preventable; therefore, meticulous attention should be taken in the postablation period to avoid factors that can precipitate these arrhythmias. It is possible that in the setting of severely compromised ventricular function, ventricular tachycardias are not well tolerated in the postablation period. In addition, loss of the atrial contribution to cardiac output or paced rates in the postablation period slower than baseline rates might have worsened ventricular function. Therefore, resuscitation measures normally effective in patients with normal ventricular function might prove unsuccessful. All patients in this present series who experienced torsades de pointes had ventricular ectopic activity in the immediate prearrest period. Nevertheless, it is not yet well understood why the majority of patients in the present series died from refractory arrhythmias after DC shock.
The clinician must carefully consider the risk-tobenefit ratio in the patient with severe left ventricular dysfunction because the possibility of postablation mortality appears high. Should ablation be denied to some patients with shock or terminal heart failure? At present, the choice to ablate in this patient group cannot be definitively based on an examination of the available data.
The following guidelines are recommended in the postablation care of these patients. There should be meticulous attention to prevention of hypokalemia and hypomagnesemia. A prolonged QTc interval in the baseline ECG may alert the physician to future problems. All patients should have continuous, careful electrocardiographic monitoring for at least 3-4 days. The postablation pacing rate should be adequate to suppress ventricular ectopic activity, shorten the QT interval, and maximize cardiac output. The rate of the pacemaker may need to be set at a faster rate than usual, possibly at more than 80 beats/min. All physicians caring for the patient should be fully aware of the patient's prior drug and arrhythmia history and avoid the use of drug classes known to cause torsades. The patient's hemodynamic status should be optimized before proceeding to ablation. In patients who have large chest walls or are massively obese, it may be useful to monitor them with large adhesive defibrillator pads already in place to aid in potential cardioversion.
Role of Radiofrequency Energy and Nonarcing Discharges for Catheter Ablation of Atrioventricular Junction
We focused on patients who have undergone DC ablation of the atrioventricular junction. At the time the study was initiated, the use of radiofrequency energy had not been used in humans for atrioventricular junction ablation. Radiofrequency energy promises to be much safer than DC energy because it obviates the need for general anesthesia, avoids the barotrauma associated with high-energy discharges, and may allow for more precise control of lesion size. Nonarcing discharges do not produce significant barotrauma.
Successful production of third-degree atrioventricular block has been reported in approximately 45% to 70% of patients after radiofrequency energy application.27-31 The use of a new catheter type has increased the success rate to 92% in one center. 32 Nonarcing discharges have been successful in 75-100% in preliminary studies in humans.33,34 Nevertheless, when radiofrequency energy or nonarcing discharges fail to produce third-degree atrioventricular block, DC may be used as a fall-back mode.
Therefore, the results reported in this report will continue to be applicable for a select group of patients. It will be of great interest to see if radiofrequency energy can avert postablation in-hospital deaths in the future. Further multicenter studies may help to clarify this matter.
Conclusion
We reported results of the first international, multicenter, prospective study of the safety and efficacy of catheter ablation. Of the 136 patients enrolled in whom only DC energy was used in attempted production of third-degree atrioventricular block, eight patients died during the ablation hospitalization. In seven patients (5.1%), the ablation procedure may have contributed to their deaths. The major cause of death was ventricular fibrillation, which occurred in three patients after documented antecedent polymorphic ventricular tachycardia. Most patients who died had severe heart disease and were hemodynamically compromised. Ablation was offered as a life-saving or palliative procedure. Predictors of death included congestive heart failure, cardiomyopathy, reduced left ventricular function, and prolonged QT interval. Hypokalemia was frequently observed in patients who developed ventricular arrhythmias. With the advent of newer, hopefully safer methods of catheter ablation, further studies are required to determine whether the complications reported in the present study may be averted.
